4507-13-5

Basic information

• Product Name: ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE
• Synonyms: OTAVA-BB BB7014320707;AURORA 20934;ART-CHEM-BB B000755;ETHYL 2-AMINO-5-ETHYL-3-THIOPHENECARBOXYLATE;ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE;AKOS B000755;AKOS MSC-0425;AKOS BBS-00004633
• CAS NO: 4507-13-5
• Molecular Formula: C₉H₁₃NO₂S
• Molecular Weight: 199.27
• EINECS: 224-824-7
• Mol File: 4507-13-5.mol

Chemical Properties

• Melting Point: 73°C
• Boiling Point: 312.7 °C at 760 mmHg
• Flash Point: 142.9 °C
• Appearance: /
• Density: 1.183 g/cm³
• Vapor Pressure: 0.00052mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE(4507-13-5)
• EPA Substance Registry System: ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE(4507-13-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 4507-13-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE is used as a reagent for the synthesis of 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines. These compounds serve as dual thymidylate synthase and dihydrofolate reductase inhibitors, which are crucial in the development of antitumor agents. ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE plays a vital role in creating potential cancer treatments by targeting key enzymes involved in tumor growth.
Used in Necroptosis Inhibition:
In the field of cellular biology and pharmacology, ETHYL 2-AMINO-5-ETHYLTHIOPHENE-3-CARBOXYLATE is also utilized as a reagent in the synthesis of Necrostatin-5 (Nec-5). Nec-5 is a necroptosis inhibitor, which is essential in studying and potentially managing conditions where the programmed necroptotic cell death pathway is overactive or dysregulated. This application highlights the compound's importance in contributing to the development of therapeutic strategies for various diseases.

InChI:InChI=1/C9H13NO2S/c1-3-6-5-7(8(10)13-6)9(11)12-4-2/h5H,3-4,10H2,1-2H3

Upstream product

• 10544-50-0 sulfur 
• 123-72-8 butyraldehyde 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 332017-62-6 2-[[(benzoylamino)thioxomethyl]amino]-5-ethyl-3-thiophenecarboxylic acid ethyl ester 
• 934393-75-6 5-ethyl-2-[3-(4-methoxy-phenyl)-thioureido]-thiophene-3-carboxylic acid ethyl ester 
• 99011-92-4 5-Ethyl-2-phenylamino-thiophene-3-carboxylic acid ethyl ester 
• 133286-76-7 2-[3-(4-Carboxy-phenyl)-thioureido]-5-ethyl-thiophene-3-carboxylic acid ethyl ester 
• 109343-21-7 5-Ethyl-2-isothiocyanato-thiophene-3-carboxylic acid ethyl ester 
• 101130-13-6 6-Ethyl-2-((E)-styryl)-3H-thieno[2,3-d]pyrimidin-4-one 
• 77373-44-5 6-Ethyl-2-pyridin-3-yl-thieno[2,3-d]pyrimidin-4-ol 
• 18593-54-9 2-benzyl-6-ethyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 18002-00-1 4-Hydroxy-6-ethyl-2-phenyl-thieno<2,3-d>pyrimidin 
• 18593-51-6 6-ethyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 18593-55-0 6-ethyl-2-p-tolyl-3H-thieno[2,3-d]pyrimidin-4-one 

Relevant articles and documents

Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines

An extension of our previous research work has resulted in a number of new ATP-competitive CK2 inhibitors that have been identified among 4-aminothieno[2,3-d]pyrimidine derivatives. The most active compounds obtained in the course of the research are 3-(5-p-tolyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5e (NHTP23, IC50 = 0.01 μM), 3-(5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5g (NHTP25, IC50 = 0.065 μM) and 3-(6-methyl-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5n (NHTP33, IC50 = 0.008 μM). Structure-activity relationships of the tested 4-aminothieno[2,3-d]pyrimidine derivatives have been studied and their binding mode with ATP-acceptor site of CK2 has been proposed. A negative effect of intramolecular hydrogen bonding in the compounds' structure is discussed.

Synthesis and antitumor activity of α-aminophosphonate derivatives containing thieno[2,3-d]pyrimidines

Abstract Two series of thieno[2,3-d]pyrimidine derivatives were designed and synthesized, in which bioactive α-aminophosphonate subunits were introduced at the N3 position through an NN bond connection. The in vitro cytotoxic activity of the novel compounds was tested against human esophageal carcinoma cells (EC109), human hepatocarcinoma cells (HepG2), human gastric carcinoma cells (MGC-803), respectively, by the MTT method. The evaluation results revealed that compounds 6mb, 6mf, 6mg, 6nd and 6nh exerted the most potent inhibition against HepG2, MGC-803 and EC109 cells, respectively. In particular, compound 6mg presented excellent inhibitory effect against HepG2 (91.2%) and MGC-803 (94.4%) cells.

A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro

Recently, the World Health Organization approved the nifurtimox- eflornithine combination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle therapies for this and associated diseases. In this study, we have synthesized a series of novel 5-nitro-2-furancarboxylamides that show potent trypanocidal activity, ～1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei with very low cytotoxicity against human HeLa cells. More importantly, the most potent analogue showed very limited cross-resistance to nifurtimox-resistant cells and vice versa. This implies that our novel, relatively easy to synthesize and therefore cheap, 5-nitro-2-furancarboxylamides are targeting a different, but still essential, biochemical process to those targeted by nifurtimox or its metabolites in the parasites. The significant increase in potency (smaller dose probably required) has the potential for greatly reducing unwanted side effects and also reducing the likelihood of drug resistance. Collectively, these findings have important implications for the future therapeutic treatment of African sleeping sickness.

KG-60-piperazine as a new heterogeneous catalyst for gewald three-component reaction

Piperazine supported on amorphous silica (KG-60-piperazine) as a basic catalyst acts in the Gewald three-component reaction of some aldehydes and ketones with malononitrile as well as ethyl cyanoacetate. The catalyst shows general utility with a variety of starting carbonyl compounds. Moreover, the catalyst can be reused for four additional cycles without significant loss of the activity. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications to view the free supplemental file.

IRAK INHIBITORS AND USES THEREOF

The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Synthesis and antimicrobial activity of novel 2-(pyridin-2-yl)thieno[2,3-d] pyrimidin-4 (3H)-ones

In the present study, some new 2-(pyridin-2-yl)thieno[2,3-d]pyrimidin-4(3H) -ones derivatives (IIa-o) were synthesized. The target compounds (IIa-o) were synthesized through the acid catalyzed condensation of 2-cyano, 3-cyano, and 4-cyano-pyridines with various 2-amino-3-carbethoxythiophenes (Ia-e). All thiophene derivatives were synthesized by Gewald reaction. The structures of the newly synthesized compounds were confirmed by UV-Visible, FT-IR, 1H-NMR, and mass spectral studies. All synthesized compounds were evaluated for their antimicrobial activity against various gram-positive and gram-negative bacterial and fungal strains. Amongst the synthesized compounds IIa, IIb, IId, IIe, and IIm were found to be active. TUeBITAK.

COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA

The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.

2-Aminothiophene derivatives in a novel synthesis of phthalimidines

New aminophthalides were synthesized from o-formylbenzoic acid and substituted 2-aminothiophenes. Two of these compounds underwent recyclization in boiling Ac2O to give the previously unknown 3-acetoxy-2-(3-cyano-4, 5-dimethylthiophen-2-yl)-1,3-dihydroisoindol-1-one and 3-acetoxy-2-(3-cyano-4,5- tetramethylenethiophen-2-yl)-1,3-dihydroisoindol-1-one. The possible reaction mechanism and factors preventing the recyclization, in particular, the formation of intramolecular hydrogen bonds in the starting phthalides, were discussed. Some reactions of the resulting compounds with C-nucleophiles in trifluoroacetic acid were investigated. Two derivatives containing 4-hydroxy-3,5-di-tert- butylphenyl substituents were studied by X-ray diffraction.

THIOPHENE CONTAINING ANALOGUES OF FLUCONAZOLE AS ANTIFUNGAL AGENTS AND PROCESS THEREOF

The present invention discloses novel compounds of the Formula (1), containing thiophene moieties and pharmaceutically acceptable salts thereof, methods for preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds.

Convenient synthesis of 2-aminothiophene derivatives by acceleration of gewald reaction under ultrasonic aqueous conditions

Under ultrasound irradiation and in the presence of H2O/Et 2NH, ethyl cyanoacetate or malononitrile can combine with-methylene carbonyl compounds and elemental sulfur to efficiently yield 2-aminothiophene derivatives within a few minutes. Products are easily obtained by simple filtration because of their spontaneous precipitation in the reaction mixtures. Copyright Taylor & Francis Group, LLC.